协和医学杂志

2020, (06) 659-664

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

瑞德西韦治疗冠状病毒感染的研究进展
Progress of Remdesivir in the Treatment of Coronavirus Infection

靳凡;谢静;陈锐;王焕玲;
JIN Fan;XIE Jing;CHEN Rui;WANG Huan-ling;Department of Infection Diseases, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;Clinical Pharmacology Research Center,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

摘要(Abstract):

2019年12月,由2019新型冠状病毒(2019-novel coronavirus,2019-nCoV)感染导致的新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)于我国武汉暴发,成为全球近十几年来,继严重急性呼吸综合征(severe acute respiratory syndrome,SARS)和中东呼吸综合征(Middle East respiratory syndrome,MERS)之后第3次暴发的冠状病毒疫情。本次COVID-19疫情传播迅速、广泛,病毒传染性强,但目前尚无针对2019-nCoV的特异性药物。瑞德西韦(remdesivir)属于核苷类似物抗病毒药,在细胞实验和动物模型上均显示出抗SARS-CoV和抗MERS-CoV活性,且在治疗埃博拉病毒感染的多中心随机对照临床试验中未见明显不良反应。因此,该药被认为是治疗2019-nCoV感染极有潜力的药物。本文对瑞德西韦治疗CoV感染的研发历程和潜在临床应用作一综述。
In December 2019,the outbreak of coronavirus disease 2019(COVID-19)occurred in Wuhan,China. It became the third outbreak of coronavirus infection after severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS)in the past decade. COVID-19 is caused by 2019-novel coronavirus(2019-nCoV)infection that has spread rapidly and extensively.2019-nCoV is highly contagious,but there is no specific antiviral drug for coronavirus at present. Remdesivir,a nucleoside analogue,showed anti-SARS-CoV and anti-MERS-CoV activities in vitro and in animal models, and showed no obvious adverse reaction in the multicenter, randomized, controlled clinical trial of Ebola virus infection. Remdesivir is considered to be the great promising drug for treating 2019-nCoV infection. This article reviewed the research history and potential clinical applications of remdesivir in the treatment of coronavirus infection.

关键词(KeyWords): 瑞德西韦;新型冠状病毒肺炎;2019新型冠状病毒;临床试验
remdesivir;coronavirus disease 2019;2019-novel coronavirus;clinical trial

Abstract:

Keywords:

基金项目(Foundation): 国家“十三五”重大新药创制专项子课题“创新药物临床评价示范性平台建设”(2019ZX09734001)

作者(Author): 靳凡;谢静;陈锐;王焕玲;
JIN Fan;XIE Jing;CHEN Rui;WANG Huan-ling;Department of Infection Diseases, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;Clinical Pharmacology Research Center,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享